# Immunevasion of Human Papillomavirus (HPV) in Vulvar Intraepithelial Neoplasia 2/3 and Anogenital Warts and Efficiency and Mechanisms of Imiquimod Treatment

> **NCT00941811** · PHASE2 · COMPLETED · sponsor: **Medical University of Vienna** · enrollment: 5 (actual)

## Conditions studied

- HPV

## Interventions

- **DRUG:** Imiquimod

## Key facts

- **NCT ID:** NCT00941811
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2009-12
- **Final completion:** 2010-05
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2015-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00941811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00941811, "Immunevasion of Human Papillomavirus (HPV) in Vulvar Intraepithelial Neoplasia 2/3 and Anogenital Warts and Efficiency and Mechanisms of Imiquimod Treatment". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00941811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*